Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPHRXQ)

• Drug Name: spiroxatrine Drug Info
• Synonyms: spiroxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5268
  ChEBI ID: CHEBI:91845
  CAS Number: CAS 1054-88-2
  TTD Drug ID: DMPHRXQ

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[6]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[7]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[8]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[9]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[10]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[11]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[12]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[13]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[14]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[15]

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[16]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[17]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[18]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[19]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[20]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[21]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[22]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[23]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[24]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[25]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[26]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[27]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[28]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[29]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[30]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[31]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[32]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[32]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[32]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[32]

Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[6]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[20]
AGN-199981	DMP5Y1A	Neuropathic pain	8E43.0	Phase 2	[33]
INDORAMIN	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[34]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[23]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[35]
A-80426	DMBC3DG	N. A.	N. A.	Terminated	[36]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[37]
SK&F-104078	DMRADBU	N. A.	N. A.	Terminated	[34]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[38]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[39]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[40]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[41]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[42]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[43]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[44]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[45]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[46]
Treximet	DMU54QB	Migraine	8A80	Approved	[47]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[48]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[2]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[3]
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Antagonist	[4]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Antagonist	[5]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 53).
• [2] Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56.
• [3] [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24.
• [4] Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95.
• [5] The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65.
• [6] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [7] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [9] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [10] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [11] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [12] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [13] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [14] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [15] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [16] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [17] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [18] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [19] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [20] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [21] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [22] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [23] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [24] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [25] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [26] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [27] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [28] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [29] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [30] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [31] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [32] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [33] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [34] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [35] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [36] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [37] alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
• [38] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [40] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [41] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [42] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [43] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [44] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [45] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [46] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [47] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [48] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)